Pharmacogenetics in future medical care -: Implications for patients and physicians

被引:6
作者
Rogausch, A
Brockmöller, J
Himmel, W
机构
[1] Univ Gottingen, Abt Allgemeinmed, Bereich Humanmed, D-37073 Gottingen, Germany
[2] Univ Gottingen, Klin Pharmakol Abt, Bereich Humanmed, D-37073 Gottingen, Germany
关键词
pharmacogenetics; ethics; physician-patient relations; genetic counselling; informed consent; family practice;
D O I
10.1055/s-2004-813918
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose: Since public acceptance of pharmacogenetic testing will largely influence their implementation in routine medical care, common implications of pharmacogenetic testing from patients', physicians' and scientists' perspective are reviewed. Methods: Broad literature review (MEDLINE; MeSH terms: Pharmacogenetics, Delivery of Health Care, Ethics, Attitude, Patient Acceptance of Health Care) of empirical and theoretical studies describing psychological, family-related, social, and ethical consequences of pharmacogenetic testing to describe. relevant aspects for further empirical studies. Results: Apart from anticipated benefit, acceptance of pharmacogenetic testing might be influenced by the following: Expectation of negative psychosocial consequences, fear of discrimination or violation of privacy. Due to its great complexity, understanding of test results and explanation of their impact pose new challenges for physician-patient relations. Since most studies are conceptual, empirical studies exploring attitudes of patients/physicians and determining medical as well as economic value of pharmacogenetic testing are imperative.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 97 条
[1]   Pharmacogenomics: Ethical concerns for research and pharmacy practice [J].
Alcalde, MG ;
Rothstein, MA .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2002, 59 (22) :2239-2240
[2]   Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group [J].
Anderson D.C. ;
Gomez-Mancilla B. ;
Spear B.B. ;
Barnes D.M. ;
Cheeseman K. ;
Shaw P.M. ;
Friedman J. ;
McCarthy A. ;
Brazell C. ;
Ray S.C. ;
McHale D. ;
Hashimoto L. ;
Sandbrink R. ;
Watson M.L. ;
Salerno R.A. ;
Cohen N. ;
Lister C.E. .
The Pharmacogenomics Journal, 2002, 2 (5) :284-292
[3]  
[Anonymous], 2003, PHARM ETH ISS
[4]   Ethical issues in human genome epidemiology: A case study based on the Japanese American family study in Seattle, Washington [J].
Austin, MA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (07) :585-592
[5]   The interface of genetics and public health: Research and educational challenges [J].
Austin, MA ;
Peyser, PA ;
Khoury, MJ .
ANNUAL REVIEW OF PUBLIC HEALTH, 2000, 21 :81-99
[6]   Clinical relevance of pharmaeogenetics [J].
Becquemont, L .
DRUG METABOLISM REVIEWS, 2003, 35 (04) :277-285
[7]   Attitudes toward genetic testing in patients at risk for HNPCC/FAP and the German population [J].
Berth, H ;
Balck, F ;
Dinkel, A .
GENETIC TESTING, 2002, 6 (04) :273-280
[8]  
Berth H, 2002, Z GESUNDHEITSPSYCHOL, V10, P97
[9]  
Brand A, 2002, GESUNDHEITSWESEN, V64, P224, DOI 10.1055/s-2002-25207
[10]   Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance [J].
Brazell, C ;
Freeman, A ;
Mosteller, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (03) :224-231